Pregnant Women Clinical Trial
Official title:
Immunization of Women With Diphtheria and Tetanus Toxoids Combined With Acellular Pertussis (Tdap) During the Mid Third Trimester of Pregnancy: An Evaluation of the Potential for Immunological Protection for the Neonate
Verified date | August 2020 |
Source | Dalhousie University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to assess whether immunization against pertussis in the mid third trimester of pregnancy provides passive protection to the infant by transfer of IgG transplacentally and by transfer of secretory IgA (and possibly IgG) in breast milk, sufficient to protect the infant against pertussis disease in the critical neonatal period, without suppressing the infant's immune response to active immunization and disease
Status | Completed |
Enrollment | 320 |
Est. completion date | December 9, 2015 |
Est. primary completion date | December 9, 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Pregnant women 18 years of age and over. - Women who, at =30-<32 weeks gestation, are at low risk for complications as determined by the obstetrical algorithm for identification of eligible subjects and the obstetrical risk assessment form. - Signed, informed consent. Exclusion Criteria: - Failure to meet eligibility criteria as determined by the obstetrical algorithm for identification of eligible subjects and the obstetrical risk assessment form. - History of significant medical disorder (such as bleeding disorders, cancer, autoimmune disease, immunodeficiency (including HIV-infected individuals, transplant recipients), seizure disorder or significant psychiatric illness, drug or alcohol dependence). - Receipt of any high-dose daily corticosteroids (inhaled steroids are acceptable) within 2 weeks of study entry. High dose is defined as a dose of =20 mg of prednisone daily or equivalent. - History of physician-diagnosed or laboratory-confirmed pertussis within the past 5 years. - Personal history (verbal or documented) of ever having received Tdap. - Personal history (verbal or documented) of having received Td immunization within the past 2 years. - History of febrile illness (>37.8ÂșC orally) within the past 72 hours (immunization may be deferred). - History of sensitivity to any component of Tdap. - Receipt of blood products or immunoglobulin within 3 months of study entry (except RH-negative women who receive immunoglobulin during pregnancy are eligible). - Receipt of any vaccines within 2 weeks of study vaccine (except influenza vaccine which may be given concurrently). - Failure to give written, informed consent. |
Country | Name | City | State |
---|---|---|---|
Canada | Clinical Trial Research Center - Canadian Center for Vaccinology | Halifax | Nova Scotia |
Lead Sponsor | Collaborator |
---|---|
Scott Halperin | IWK Health Centre, Sanofi Pasteur, a Sanofi Company |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of serum IgG antibody levels against PT, FHA, PRN, FIM between Tdap and Td groups | birth, 2, 4, 6, 7, 12, and 13 months of age | ||
Secondary | Safety of Tdap in pregnancy including pregnancy outcome and developmental assessment. | developmental screening at 1 year of age |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03955263 -
Malaria In Pregnancy in Central India
|
||
Not yet recruiting |
NCT04457947 -
Exploring Aromatherapy Intervention in Acute Care
|
||
Active, not recruiting |
NCT01397318 -
Effects of Modified TaiChi Exercise on Maternal Stress, Fatigue, Sleep Quality, Biomarkers, and Infant Gestational Age and Birthweight
|
N/A | |
Completed |
NCT00639145 -
Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol
|
||
Not yet recruiting |
NCT00931099 -
Fetal Outcome of Sleep Disordered Breathing During Pregnancy
|
N/A | |
Recruiting |
NCT00751569 -
microRNA Profile in Umbilical Cord Blood NK Cells
|
N/A | |
Completed |
NCT06111716 -
Mindfulness in Childbirth Preparation Education Process
|
N/A | |
Completed |
NCT05729191 -
Evaluation of the Acceptance of the Anti-COVID-19 Vaccine Offer Among Pregnant Women
|
||
Completed |
NCT01687634 -
Home Visiting for Low Income, Pregnant Women
|
N/A | |
Recruiting |
NCT05446571 -
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir
|
Phase 3 | |
Not yet recruiting |
NCT03651934 -
Verification of Correlation Between Genetic Testing of Nutritional Metabolism and Clinical Biochemical Indicators
|
N/A | |
Active, not recruiting |
NCT06422130 -
Ningbo Maternity-Child Linked Database Study
|
||
Completed |
NCT02904473 -
Goals for Reaching Optimum Wellness (GROWell)
|
N/A | |
Completed |
NCT03538106 -
Factors Associated With Cesarean Delivery in Women With Type 1 Diabetes
|
||
Recruiting |
NCT01246765 -
National Pregnancy Registry for Psychiatric Medications
|
||
Recruiting |
NCT05916534 -
We Care About Brooklyn - A Digital Behavioral Intervention to Optimize Engagement in Maternal Healthcare
|
N/A | |
Completed |
NCT04264910 -
CALM Pregnancy: Feasibility of Calm for Pregnant Women
|
N/A | |
Completed |
NCT04494581 -
GriCoVax Study in 4 Maternity Wards in the Ile-de-France Region
|
||
Recruiting |
NCT05349279 -
Qatar PREgnancy Covid-19 OUtcome Study
|
||
Withdrawn |
NCT04354441 -
Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women
|
Phase 2 |